Quotient expands Reading facility tripling GMP capacity

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Jirsak)
(Image: Getty/Jirsak)

Related tags: facility, Capacity utilization, Manufacturing, Clinical trial, Supply chain

Quotient Sciences expanded its formulation development and clinical trial manufacturing operations at its Reading, UK facility.

The drug development services company’s investment increased the site’s good manufacturing practices (GMP) capacity and added new equipment for oral solid dose manufacturing.

Quotient’s 48,000-square-foot facility develops small molecule drug products for oral and inhaled delivery, providing characterization formulation development and clinical trial manufacturing services.

The Reading, UK site features 13 GMP manufacturing suites supporting Phase I-III clinical trial manufacturing, and the company’s Translational Pharmaceutics programs, which combines formulation with real-time drug product manufacturing and clinical testing.

Batch sizes can be tailored to fit the needs of a clinical trial with this type of manufacturing suite, according to Quotient.

It can handle poorly soluble compounds and is equipped with technologies including spray drying, hot melt extrusion, lipidic systems, and micronization.

Mark Egerton, CEO of Quotient Sciences, explained, “With drug development expertise on both sides of the Atlantic, we are optimally positioned to serve our global client base.”

Quotient acquired the contract development and manufacturing organization (CDMO) Pharmaterials​ in 2017. The site in which this recent expansion has been made formerly housed Pharmaterials. At the time of the acquisition, Quotient noted that the site had room for future expansion.

Reading is one of Quotient’s six operating sites in the UK and US.

Expanding presence and operations

Quotient has worked on expanding its global presence in recent years with multiple acquisitions and a renaming from Quotient Clinical to Quotient Sciences.

 In 2017, Quotient acquired SeaView Research in an aim to expand its US footprint.

The SeaView acquisition followed on the company’s strategic move to secure a place in the US market, which Egerton previously said​ was “an important strategic objective for Quotient to support continued growth and expansion.”

Around the same time as the SeaView acquisition, Quotient acquired QS Pharma LLC., Charles River Laboratories’ contract manufacturing business, for $75m.

In October of 2018, Quotient made a $15m investment into a new site​ to expand its US manufacturing operations. The 45,000-square-foot facility located near Philadelphia, PA will be a center of excellence for early-phase formulation development and clinical trial manufacturing.

In 2018 Quotient also partnered with PPD in a collaboration to accelerate pediatric drug development​ through Quotient’s Translational Pharmaceuticals. 

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more